Archives of the
Turkish Society of Cardiology
Original Article

The Effects of Iron Replacement on Functional Capacity in Patients with Group 1 and Group 4 Pulmonary Hypertension

1.

Department of Cardiology, Marmara University Pendik Training and Research Hospital, İstanbul, Turkey

2.

Department of Pulmonology, Marmara University Pendik Training and Research Hospital, İstanbul, Turkey

3.

Department of Thoracic surgery, Marmara University Pendik Training and Research Hospital, İstanbul, Turkey

Archives of the Turkish Society of Cardiology 2022; 50: 492-497
DOI: 10.5543/tkda.2022.22343
Read: 743 Downloads: 127 Published: 01 October 2022

Objective: Abnormal iron handling complicates pulmonary hypertension (PH), causes functional limitation and poor outcomes. Although preliminary results in group 1 PH patients support the use of iron replacement, whether this applies to other PH subgroups is not known.

Methods: A total of 58 patients with an established diagnosis of group 1 or 4 PH, who had a serum ferritin of <100 ng/mL or 100 to 300 ng/mL in combination with a transferrin saturation (TSAT) <20% and received 500 to 1000 mg of ferric carboxymaltose (FCM) were included in the study. The change in ferritin levels and TSAT were calculated at 12- and 24-weeks follow-up. A six-minute walk test (6MWT) is undertaken at the first, 12-week and 24-week follow-up visits.

Results: In group 1 PH patients, ferritin levels increased from 14 ng/mL-1 to 133 and 90 ng/mL-1 at 12- and 24-weeks, respectively ( P < .001 for both). In group 4 PH patients, ferritin levels increased from 22.1 ng/mL-1 to 145 and 88.9 ng/mL-1 at 12- and 24-weeks, respectively ( P < .001 for both). 6MWT distances were 356, 412, and 350 m in group 1 PH patients and 260, 315 and 290 m in group 4 PH patients. Although the difference between baseline and 12-week 6MWT was significant in both groups ( P < .001 for both), this difference was lost at 24-week.

Conclusion: Our study indicates that there is no difference in response to iron replacement in patients with group 1 and group 4 PH patients, in terms of treatment success and functional status.

Cite this article as: Akaslan D, Aslanger E, Ataş H, et al. The effects of iron replacement on functional capacity in patients with group 1 and group 4 pulmonary hypertension. Turk Kardiyol Dern Ars. 2022;50(7):492-497.

Files
TURKISH
ISSN 1016-5169 EISSN 1308-4488